Allergan, Restasis Buyers Can't Agree On MDL Venue

By Carolina Bolado (January 25, 2018, 8:44 PM EST) -- All parties involved in antitrust suits claiming Allergan Inc. delayed the launch of generic versions of its dry-eye medication Restasis — in part by transferring patents to a Native American tribe — agreed Thursday that the Judicial Panel on Multidistrict Litigation should consolidate the cases, but they differed on the venue when they pitched Texas, California and New York as options....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!